Solid Carcinoma
30
12
15
7
Key Insights
Highlights
Success Rate
70% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
10.0%
3 terminated out of 30 trials
70.0%
-16.5% vs benchmark
0%
0 trials in Phase 3/4
43%
3 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (30)
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors
A Study of Avutometinib for People With Solid Tumor Cancers
Thrombin Generation and Prediction of Thromboembolic Events in Oncology Patients at Risk
A Study of DM005 in Patients With Advanced Solid Tumors
A Study of DM002 in Patients With Advanced Solid Tumors
Trop2-targeted immunoPET Imaging of Solid Tumors
FMT With Nivolumab in Patients With Advanced Solid Cancers Who Have Progressed During Anti-PD-(L)1 Therapy
PET [89Zr]DFO-starPEG in Solid Tumors
Imaging of Solid Tumors Using 18F-TRX
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
A Study of DM001 in Patients With Advanced Solid Tumors
PRE-I-SPY Phase I/Ib Oncology Platform Program
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Prevention of Chest Pain in Chemo-treated Cancer Patients